ClinicalTrials.gg
Not yet recruitingNCT07917312FROSTUpdated Nov 4, 2026

Evaluating Sucrose and Cold Oral Interventions for the Treatment of Oral Pruritus During Allergy Procedures.

An interventional study of Food (sucrose) and Food (popsicle) in Allergy, Food Allergies and Oral Pruritus, sponsored by Philippe Bégin. Not yet recruiting at 2 sites in Canada. Open to participants aged 8 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Primary conditionFood HypersensitivityRegistry: HypersensitivityReclassifiedWhy we changed it
Registry
Hypersensitivity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Food Hypersensitivity
Why
  1. The study's listed conditions name Food Hypersensitivity, a narrower term within Hypersensitivity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Philippe Bégin · Not applicable, Interventional, and Treatment

Updated Nov 4, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
8 Years and older
Sex
All
01

Study summary

This is a two-center, randomized, open-label, factorial controlled trial. This trial aims to evaluate the efficacy of exposure to sucrose and ice, alone and in combination, compared to control, in reducing oral pruritus during allergy procedures.

The population will include patients aged 8 years and older presenting with oral pruritus in the context of an oral food challenge or an oral immunotherapy dose increase at the allergy clinic.

Clinically significant oral pruritus will be defined as a pruritus intensity of ≥3/10 on the ICH NRS, and a symptom bothersome enough that the patient would normally seek treatment.

Eligible participants will be randomized to one of four groups (1:1:1:1 ratio):

  • Sucrose only (3.5 g granulated sugar)
  • Cold only (20 mL of ice in the form of popsicle)
  • Sucrose + cold (20 mL frozen sucrose solution)
  • Control (20 mL room-temperature water)

Participants will be asked to report when the pruritus has decreased to a level at which they would not normally seek treatment, as well as when it has completely resolved.

The evolution of oral pruritus will be assessed using an 11-point Numeric Rating Scale (ICH NRS). Pruritus intensity will be measured every 30 seconds during the first 5 minutes after administration of the study intervention and then every 1 minute until 15 minutes post-intervention.

02

Conditions studied

  • Allergy
  • Food Allergies
  • Oral Pruritus
  • Environmental Allergies

Browse trials for

03

In context

Food Hypersensitivity Reclassified

348 studies on the registry are indexed under Food Hypersensitivity; 90 are open to participants now.

This study's planned enrollment of 48 is below the median of 60 across 219 interventional studies indexed under Food Hypersensitivity.

Browse Food Hypersensitivity studies →

Lead sponsor

Philippe Bégin is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Compared within Food Hypersensitivity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypersensitivity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
8 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 8 years and older.
  • Have a clinically diagnosed IgE-mediated food allergy, supported by a compatible clinical history and evidence of IgE sensitization (e.g., skin prick testing and/or serum food-specific IgE), as determined by the treating allergist.
  • Undergoing an oral food challenge or initiating oral immunotherapy / undergoing an oral immunotherapy dose escalation.
  • Develop oral pruritus following allergen administration with a minimum score of 3/10 on the ICH Numeric Rating Scale (ICH NRS).
  • Be able to assess and report their symptoms using the ICH NRS.
  • Provide informed consent to participate in the study (and assent, where applicable, in accordance with local regulations).

Exclusion criteria

Exclusion Criteria:

  • Any oral condition or pathology that could interfere with the perception, assessment, or interpretation of oral pruritus symptoms.
  • Presence or development of systemic allergic symptoms for which epinephrine administration would be clinically indicated.
  • Poorly controlled diabetes mellitus, as defined by the treating physician.
  • Any condition affecting oral sensation or the ability to accurately communicate symptoms using the ICH NRS.
  • Cold urticaria or significant hypersensitivity to cold.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Active comparator
    Sucrose only

    3.5 g granulated sugar

    Other: Food (sucrose)

  • Active comparator
    Cold only

    20 mL of ice in the form of popsicle

    Other: Food (popsicle)

  • Active comparator
    Sucrose and cold

    20 mL frozen sucrose solution

    Other: Food(Sucrose and cold)

  • Placebo comparator
    Water

    20 mL room-temperature water

    Other: Water (Placebo)

Interventions

  • OtherFood (sucrose)

    Sucrose only (3.5 g granulated sugar)

  • OtherFood (popsicle)

    Cold only (20 mL of ice in the form of popsicle)

  • OtherFood(Sucrose and cold)

    Sucrose + cold (20 mL frozen sucrose solution)

  • OtherWater (Placebo)

    20 mL room-temperature water

06

What researchers measure

Primary outcomes

  1. Area under the curve (AUC) of ICH NRS scores

    Pruritus intensity will be assessed using the Numerical Rating Scale (NRS), ranging from 0 (no itch) to 10 (worst imaginable itch). Higher scores indicate greater pruritus intensity and therefore a worse outcome.

    Time frame: From baseline (pre-intervention) through 15 minutes post-intervention.

Secondary outcomes

  1. Time to reduction of at least 2 points from the baseline ICH NRS score.

    A reduction of at least 2 points on the 11-point Numerical Rating Scale (0-10) indicates an improvement in pruritus intensity.

    Time frame: From baseline (pre-intervention) through 15 minutes post-intervention.

  2. Time to complete resolution of oral pruritus (ICH NRS score of 0).

    Complete resolution of oral pruritus is defined as an Intra-episode Clinical Numerical Rating Scale (ICH NRS) score of 0, corresponding to no itching. The scale ranges from 0 (no itch) to 10 (worst imaginable itch), with higher scores indicating greater pruritus severity and therefore a worse outcome.

    Time frame: From baseline (pre-intervention) through 15 minutes post-intervention.

  3. Time to a decrease in oral pruritus intensity to a level at which the participant would normally not seek treatment.

    Time from intervention administration to the first assessment at which oral pruritus intensity decreases to a level that the participant reports would not normally prompt them to seek treatment. Pruritus intensity is assessed using the Intra-episode Clinical Numerical Rating Scale (ICH NRS), ranging from 0 (no itch) to 10 (worst imaginable itch), with higher scores indicating greater pruritus intensity and a worse outcome.

    Time frame: From baseline (pre-intervention) through 15 minutes post-intervention.

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jun 2027, 7 months later.

Of 83 non-industry interventional studies with no phase under Food Hypersensitivity, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 50. This study's planned 7 months is below that.

Counting every sponsor, half of 86 studies reached it within 29 months; a quarter within 13 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2026
First posted
Nov 4, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Aug 1, 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07917312
Lead sponsor
Philippe Bégin
Collaborators
Centre hospitalier de l'Université de Montréal (CHUM), Sainte Justine Hospital Research Institute
Responsible party
Philippe Bégin (Principal Investigator, St. Justine's Hospital) — Sponsor-investigator
First posted
Nov 4, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Jun 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Ginevra Lacatusu
Contact
ginevra.lacatusu.hsj@ssss.gouv.qc.ca
514-345-4931 ext. 2670

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion